
Renovos Biologics is excited to announce the FDA's Breakthrough Device Designation for its leading product, RENOVITE® BMP-2. This innovative bone graft material, utilizing a proprietary synthetic nanoclay gel, aims to be a safer and more efficient alternative. The injectable gel, containing the growth factor BMP-2, facilitates precise, localized bone formation without leaching. The Breakthrough Designation expedites development and review, ensuring timely access to potentially life-saving medical devices. Renovos will benefit from increased collaboration with FDA experts and prioritized reviews during the submission process.
Like
Save
Share